Child outcomes after amnioinfusion compared with no intervention in women with second-trimester rupture of membranes : a long-term follow-up study of the PROMEXIL-III trial by de Ruigh, A. A. et al.
Child outcomes after amnioinfusion compared
with no intervention in women with second‐
trimester rupture of membranes: a long‐term
follow‐up study of the PROMEXIL‐III trial
AA de Ruigh,a NE Simons,a J van ’t Hooft,a AS van Teeffelen,b RG Duijnhoven,a
AG van Wassenaer‐Leemhuis,c C Aarnoudse‐Moens,c C van de Beek,d D Oepkes,e MC Haak,e
M Woiski,f MM Porath,g JB Derks,h LEM van Kempen,a TJ Roseboom,d BW Mol,i E Pajkrta
a Department of Obstetrics and Gynaecology, AcademicMedical Centre (AMC), Amsterdam, TheNetherlands b Department of Obstetrics and
Gynaecology, Grow, School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC),Maastricht, The
Netherlands c Department of Neonatology, Emma Children’s Hospital AcademicMedical Centre (AMC), Amsterdam, The Netherlands
d Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, AcademicMedical Centre (AMC),
Amsterdam, The Netherlands e Department of Obstetrics and Gynaecology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands
f Department of Obstetrics and Gynaecology, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands g Department of
Obstetrics and Gynaecology, MaximaMedical Centre (MMC), Veldhoven, The Netherlands h Department of Obstetrics and Gynaecology, University
Medical Centre Utrecht (UMCU), Utrecht, The Netherlands i Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia
Correspondence: AA de Ruigh, Department of Obstetrics and Gynaecology, Academic Medical Centre (AMC), Meibergdreef 9, 1105 AZ
Amsterdam, Netherlands. Email: a.a.deruigh@amc.uva.nl
Accepted 7 January 2020. Published Online 4 March 2020.
Objective To assess the effect of transabdominal amnioinfusion or
no intervention on long‐term outcomes in children born after
second‐trimester prelabour rupture of the membranes (PROM
between 16+0/7–24+0/7 weeks) and oligohydramnios.
Population Follow up of infants of women who participated in
the randomised controlled trial: PPROMEXIL‐III (NTR3492).
Methods Surviving infants were invited for neurodevelopmental
assessment up to 5 years of corrected age using a Bayley Scales of Infant
and Toddler Development or a Wechsler Preschool and Primary Scale
of Intelligence. Parents were asked to complete several questionnaires.
Main outcome measures Neurodevelopmental outcomes were
measured. Mild delay was defined as −1 standard deviation (SD),
severe delay as −2 SD. Healthy long‐term survival was defined as
survival without neurodevelopmental delay or respiratory problems.
Results In the amnioinfusion group, 18/28 children (64%) died
versus 21/28 (75%) in the no intervention group (relative risk 0.86;
95% confidence interval [CI] 0.60–1.22). Follow‐up data were
obtained from 14/17 (82%) children (10 amnioinfusion, 4 no
intervention). In both groups, 2/28 (7.1%) had a mild
neurodevelopmental delay. No severe delay was seen. Healthy long‐
term survival occurred in 5/28 children (17.9%) after amnioinfusion
versus 2/28 (7.1%) after no intervention (odds ratio 2.50; 95% CI
0.53–11.83). When analysing data for all assessed survivors, 10/14
(71.4%) survived without mild neurodevelopmental delay and 7/14
(50%) were classified healthy long‐term survivor.
Conclusions In this small sample of women suffering second‐
trimester PROM and oligohydramnios, amnioinfusion did not
improve long‐term outcomes. Overall, 71% of survivors had no
neurodevelopmental delay.
Keywords Follow up, infant development, neurodevelopment,
oligohydramnios, second‐trimester prelabour rupture of the
membranes.
Tweetable abstract Healthy long‐term survival was comparable for
children born after second‐trimester PROM and treatment with
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Second‐trimester prelabour rupture of membranes (PPROM
between 16+0/7 and 24+0/7 weeks of gestation) complicates
0.4–0.7% of all pregnancies and results in high rates of peri-
natal morbidity and mortality.1–3 After second‐trimester
PROM, an immature delivery may arise. Ongoing pregnan-
cies are challenged by lack of amniotic fluid (oligohydram-
nios), which is crucial for pulmonary development.4,5
Consequently, outcomes of pregnancies complicated by
second‐trimester PROM are poor due to high rates of pul-
monary hypoplasia, neonatal and maternal infection, and
extremely premature delivery.6
Serial transabdominal amnioinfusion could restore residual
amniotic fluids and thus reduce the rate of pulmonary hypo-
plasia, severe respiratory failure, and cardiovascular problems
such as pneumothorax and persistent pulmonary hyperten-
sion of the neonate (PPHN). Furthermore, it may prevent
compression of the umbilical cord and skeletal deformities,
and increase time to delivery.7 Recently, two multicentre ran-
domised controlled trials (RCTs; AMIPROM trial and PPRO-
MEXIL‐III trial) have been published investigating whether
amnioinfusion improves outcomes for PPROM in the previ-
able period.8,9 No statistically significant differences were
observed in perinatal, pregnancy or maternal outcomes. The
AMIPROM trial was the first trial to evaluate not only short‐
term outcomes but also long‐term respiratory and neurodevel-
opmental outcomes. Performing a pilot study, the trial found
no significant difference in the overall chance of survival with-
out long‐term respiratory or neurodevelopmental disability
(4/28 children [14.3%] in the amnioinfusion group versus 0/
28 children in the no intervention group, relative risk [RR]
9.0; 95% confidence interval [CI] 0.51–159.70). Even though a
significant beneficial effect from serial transabdominal
amnioinfusion could not be demonstrated in women with sec-
ond‐trimester PROM, the AMIPROM study did suggest that
amnioinfusion might lead to an improvement in long‐term
healthy survival of children. Observation of the children in
early and later childhood seems appropriate, as children
born after second‐trimester PROM are more likely to show
long-term respiratory symptoms and neurodevelopmental
impairments due to perinatal morbidity caused by intrauter-
ine infection or oligohydramnios. Therefore, we aimed to
compare the neurodevelopmental outcome and healthy sur-
vival of children up to 5 years of age, born to mothers with
second‐trimester PROM and oligohydramnios, randomised to
amnioinfusion or no intervention.
Material and methods
Participants
We performed a follow‐up study of the PPROMEXIL‐III
trial (NTR 3492). Details of the PPROMEXIL‐III trial have
been published elsewhere.9,10 In summary, 56 women with
second‐trimester PROM between 16+0/7 and 24+0/7 weeks’
gestation were included, 28 women randomised to
amnioinfusion and 28 to no intervention.
The follow‐up study took place between November 2017
and March 2018, and was approved by the Medical Ethics
Committee of the Academic Medical Centre (AMC), Ams-
terdam, The Netherlands (ref. no. MEC 2016_218,
NL58495.018.16). All children born to women who had
participated in the PPROMEXIL‐III trial and were alive at
discharge (n = 17) were invited for an extensive follow‐up
assessment up to 5 years of corrected age, calculated from
estimated date of delivery until the date of assessment.
Children were assessed for neurodevelopmental and respi-
ratory outcomes. Secondary outcomes such as behavioural,
sensory processing, and health outcomes were assessed. A
power calculation before start of the follow‐up study
showed that a sample size of six children in each group
would be sufficient to detect a difference of 30 points (−2
standard deviations [SD]) in the Bayley Scales of Infant
Development – 3rd edn Dutch version (Bayley‐III‐NL)11 or
Wechsler Preschool and Primary Scale of Intelligence – 3rd
edn Dutch version (WPPSI‐III‐NL)12 test with a power of
80%, a two‐sided α of 0.05, and ß of 0.20.
Follow‐up assessment
Medical records were checked for possible occurrence of
death of women’s offspring before contacting parents for
participation in the follow‐up study by telephone. Written
informed consent was obtained prior to the examination.
Parents were asked to complete four different question-
naires: a respiratory questionnaire, Child Behaviour Check-
list (CBCL 1.5‐5),13 the Infant/Toddler Sensory Profile
(ITSP)14 or Sensory Profile (SP‐NL),15 and a health ques-
tionnaire. To assess neurodevelopmental outcome, a neu-
ropsychologist and/or a neonatologist, blinded for the
study group, administered a Bayley‐III‐NL or WPPSI‐III‐NL,
as appropriate for the child’s age. In case neurodevelopmen-
tal tests (i.e. Bayley‐III‐NL) or behavioural questionnaires
(CBCL) had already been administered during standardised
neonatal follow‐up visits (a national follow‐up programme
for extremely premature infants16), these results would be
collected after written informed consent of the parents had
been obtained.
Neurodevelopmental assessment and respiratory
outcomes
The Bayley‐III‐NL and WPPSI‐III‐NL are both designed to
chart a child’s cognitive developmental level. The Bayley‐III‐NL
also assesses motor development.11,17 The test appropriate
for the child’s age was administered. A validation study
showed significant correlation between the Bayley‐III‐NL
and WPPSI‐III‐NL, and underlines the relation between
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both tests.18 Dutch versions of both tests were used, with
scores based on Dutch validated norms scores.12 The Bayley‐
III‐NL assessments were used for children with a corrected
age of <42 months. This test reports outcomes in two sub-
scales: the Cognitive Composite Score (CCS) and the Motor
Composite Score (MCS). The WPPSI‐III‐NL was used to
measure cognitive development of children ≥42 months old.
Outcomes were reported in three index scores: Performance
IQ (PIQ), Verbal IQ (VIQ), and Full‐Scale IQ (FSIQ). Both
tests have a mean score of 100 points with a SD of 15 points.
An index score ≤70 (i.e. more than −2 SD below the mean
score) was considered severe neurodevelopmental delay, a
score >70 and ≤85 (i.e. −1 SD) mild delay. Normal neurode-
velopment outcome was defined as no severe or mild neu-
rodevelopmental delay (i.e. score >85) on both Bayley‐III‐NL
index scores or on any of the three WPPSI‐III‐NL index
scores. Below 42 months, the MCS of the Bayley was
included in the outcome measure neurodevelopmental delay
because cognitive and motor development are strongly inter-
connected at early ages.19
Assessment of respiratory problems: respiratory
questionnaire
Respiratory problems were assessed using a parental respi-
ratory questionnaire and defined as symptoms interfering
with daily activities (i.e. not able to attend school or not
able to play) at least once a week over the past 4 weeks, or
use of anti‐asthmatic medication at least one or more
times/week (from birth until current age), or visits to a
pulmonologist (from birth until current age).
Secondary outcomes
Behavioural assessment
The CBCL for age 1.5–5 years (CBCL 1.5–5) was used to
assess behavioural and emotional problems and informs on
eight subscales: emotionally reactive, anxious or depressed,
somatic complaints, withdrawn, sleep problems, attention
problems, and aggressive behaviour.13,20 Data from these
scales can be summed to provide a combined total problem
score and two broad dimensions scores (internalising prob-
lems and externalising problems). A score >90th percentile
in one of the two broad dimensions or the total problem
score of the CBCL was defined as abnormal and clinically
relevant for indicating serious behavioural problems.
Assessment of sensory processing
The ITSP and SP‐NL were used to assess sensory processing
in children <36 months (ITSP) and ≥36 months old (SP‐
NL).14,15 The test appropriate for the child’s age was used.
The ITSP and SP‐NL report four sensory quadrants: Low
Registration, Sensory Sensitivity, and Sensation Avoiding.
The higher the quadrant score, the lower the responsiveness
of the child.21 Quadrant scores are interpreted relative to
age norms and described as typical performance (≤1 SD),
probable difference (between −1.0 and −2.0 SD), and defi-
nite difference (± 2 SD). A score of ± 2 SD in any four
sensory quadrants of the ITSP and SP‐NL was considered
an abnormal outcome and indicated a definite difference in
sensory processing.
Assessment of health outcomes
A health questionnaire was used to address demographic
variables and healthcare use of the children until 5 years of
age. Healthcare use was clustered into clinically relevant
groups (i.e. visits to healthcare provider or developmental
care specialists, use of medication, hospital admission, and
need for surgery) and divided into different age groups (i.e.
before 2 years of age and after 2 years of age). Visits to a
healthcare provider were divided into visits to the general
practitioner or a specialist. Medication use was categorised
as use of one or more medicines or no medication use at
all. To prevent multiple comparisons, one analysis per clin-
ically relevant group was performed.
Statistical analysis
Differences in infant and demographic characteristics,
maternal, pregnancy, and delivery characteristics, as well as
short‐term neonatal characteristics were compared between
the amnioinfusion versus the no intervention group in chil-
dren who participated in follow up, between follow‐up par-
ticipants versus children lost to follow up, and between
deceased children versus all surviving children using an inde-
pendent sample t‐test, Mann–Whitney U‐test, Chi‐square
test or Fisher’s exact test as appropriate. Considering age dif-
ferences, only validated cut‐off scores were used, correlating
to means, SDs or percentiles, adjusted per questionnaire for
specific age groups. The clinically important composite out-
come ‘healthy long‐term survival’, defined as survival with
normal neurodevelopment and without respiratory prob-
lems, was calculated. All outcomes were reported in relation
to trial assignment and for all surviving children participat-
ing in follow up (irrespective of trial assignment) All out-
comes were analysed using the intention‐to‐treat principle. If
possible, RR or odds ratio (OR), mean or median difference
(MD), and their corresponding 95% CIs were calculated.
Due to small groups, adjusting for potential confounders
was not possible, and therefore no adjusted RRs were calcu-
lated. A P‐value of <0.05 was considered to indicate statisti-
cal significance. All analyses were conducted in IBM SPSS
statistics version 24.0 (IBM Corp., Armonk, NY, USA).
Sensitivity analysis
A sensitivity analysis assessing children lost to follow up
was performed using multiple imputation (10 datasets).
The following variables were used as predictors when
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imputing missing values using multiple imputation tech-
niques: gestational age, latency period (time from PPROM
to delivery), ethnicity, maternal age, smoking at beginning
of pregnancy, neonatal outcomes: birthweight, neonatal
sepsis, IRDS, PVL, IVH, NEC, CLD, gender of the neonate,
congenital deformities. Also, we performed a best‐case sce-
nario (all children lost to follow up were healthy) and
worst‐case scenario (all children lost to follow up had an
abnormal outcome) for the composite outcome ‘healthy
long‐term survival’.
Patient involvement
No patients or patient/parent organisations have been
involved in the development of this trial.
Results
In the PPROMEXIL‐III trial, 56 women were randomised
to amnioinfusion (n = 28) or no intervention (n = 28). In
the amnioinfusion group, 18 children died: 13 (46%)
antepartum and five (18%) postpartum. In the no
intervention group, 21 children died: 15 (54%) antepartum
and six (21%) postpartum (RR for death at any time after
amnioinfusion versus no intervention 0.86; 95% CI 0.60–
1.22). There were no deaths after discharge. Seventeen sur-
viving children (30%) were eligible for participation in this
follow‐up study: 10 (35.7%) in the amnioinfusion group
versus 7 (25%) in the no intervention group (RR for being
alive at follow‐up assessments 1.43; 95% CI 0.63–3.22)
(Figures 1 and S1). Children were seen for a follow‐up
assessment between 2 and 5 years of corrected age. Follow‐
up data were obtained from 14/17 (82%) surviving chil-
dren, 10/10 (100%) in the amnioinfusion and 4/7 (57%) in
the no intervention group. One child could not be
approached because of social services’ involvement and a
secret living address, and for two children no informed
consent was provided by the parents due to lack of time
and no interest in participating in research.
Baseline characteristics
No differences in infant, maternal, pregnancy or delivery
characteristics were found for surviving children
Figure 1. Flowchart of all participating mothers in the PPROMEXIL‐III trial and their children in the follow‐up study.
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participating in follow up according to randomisation
group, apart from white cell count in maternal serum at
randomisation, which was significantly lower in the
amnioinfusion group than in the no intervention group:
10.1 9 109/l (7.8–11.5) versus 13.6 9 109/l (10.5–16.2);
P = 0.045 (Tables 1 and S1). When comparing children
who participated in follow up (n = 14) with children lost
to follow up (n = 3) a difference was seen in gestational
age at second‐trimester PROM: 19.5 weeks (1.9) in follow
up versus 16.6 weeks (0.8) in lost to follow‐up group;,
P = 0.018. Furthermore, attrition was not related to base-
line characteristics (Table S2).
Neurodevelopmental outcome and respiratory
outcomes
No severe abnormal neurodevelopmental delay was seen in
surviving children (Table 2). Also, there were no differences
in mean index scores of the CCS and MCS for Bayley‐III‐
NL and of the PIQ for WPPSI‐III‐NL (Table S3). Due to
missing scores in the no intervention group, the VIQ and
FSIQ could not be compared. A mild delay (−1 SD) was
seen in two children in each treatment group (Table 2. For
pregnancy details of children with a mild neurodevelop-
mental delay, please see Table S4. By accident, for one
child, the MCS was not administered by the neuropsychol-
ogist; however, the neurodevelopmental parental report
indicated a normal motor development and the outcome
was therefore classified as normal. For two children, a
number of subscales of the WPPSI‐III‐NL were not per-
formed, due to delayed performance or child’s limited
understanding of tasks. A team consisting of a neuropsy-
chologist and a neonatologist classified the missing
subscales as −1 SD index scores based on the neurodevelo-
pmental reports (Table S5).
Table 2 shows the descriptive data regarding respiratory
problems. Parents of five children reported respiratory
problems, four in the amnioinfusion and one child in the
no intervention group, with three children reporting respi-
ratory problems interfering with daily activities (n = 1),
use of anti‐asthmatic medication (n = 1) or visits to a pul-
monologist (n = 1). Two children reported anti‐asthmatic
medication use as well as pulmonologist visits.










Maternal characteristics at randomisation
Age at randomisation, mean ± SD in years 33.9 ± 4.9 33.0 ± 6.9 34.4 ± 5.1 29.8 ± 5.6
Parental education*, n (%)
High Not reported Not reported 7 (70%) 2 (50%)
Middle 3 (30%) 2 (50%)
Low 0 0
Pregnancy and at delivery characteristics
Gestational age at PPROM, mean ± SD
in days
18.7 ± 1.9 18.6 ± 2.3 19.6 ± 1.3 18.9 ± 2.9
Gestational age at delivery, median (IQR)
in days
24.2 (21.5–28.0) 23.6 (20.7–27.4) 29.6 (26.9–35.9) 30.0 (27.9–35.9)






Gender male, n (%)
All pregnancies 18 (64.3%) 17 (60.7%) 10 (100%) 3 (75%)
Live‐born neonates 13 (86.7%) 7 (53.8%)
Apgar score <7 after 5 min, n (%) 10 (66.7%) 9 (69.2%) 5 (50%) 2 (50%)
Birthweight, median (IQR) in kg 1050 (735–1950) 1015 (790–1478) 1517.5 (1020.0–2397.5) 1562.5 (900.0–2723.8)
Infant characteristics at follow up
Living in two‐parent family,** n (%) n/a n/a 9 (90%) 4 (100%)
N/A, not applicable.
*Parental education: ‘low’, defined as total years post elementary schooling <6 years. Classified as ‘low’ if at least one of the parents has a low
level of education (but not if one parent is highly educated). ‘Middle’ defined as total years post elementary schooling 6–8 years. Classified as
‘middle’ if both parents had this level of education. ‘High’ defined as total years post elementary schooling >8 years. Classified as ‘high’ if one of
the parents was highly educated. Parental education was measured at the time of the follow‐up study.
**Living in two parent family: children living with one or two biological parents, new marriage and de facto relationship.
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Healthy long‐term survival
The composite outcome ‘healthy long‐term survival’
occurred in 5/28 (17.9%) children in the amnioinfusion
and 2/28 (7.1%) children in the no intervention group (RR
2.50; 95% CI 0.53–11.83) (Table 2). When assessing chil-
dren lost to follow up for a sensitivity analysis using multi-
ple imputations, being a healthy survivor occurred more
often in children in the amnioinfusion group than children
in no intervention group (Table S6). However, when
assessing healthy long‐term survival for the best case (all
children lost to follow up were healthy) or worst‐case sce-
nario (all children lost to follow up had an abnormal out-
come) for a sensitivity analysis, no differences between the
amnioinfusion group and control group were shown
(Table S7).
Secondary outcomes: behaviour, sensory
processing and health
Abnormal cut‐off scores for behaviour and sensory process-
ing outcomes are shown in Table S8. No differences were
observed between the treatment groups. Table S9 shows
that there were no differences in health outcomes of chil-
dren in the amnioinfusion group compared with the no
intervention group.
Analysing data irrespectively of trial assignment
Of 56 pregnancies complicated by second‐trimester PROM,
there were 17 live births (30.4%) (Figure 2). When comparing
baseline characteristics of survivors versus non‐survivors, we
show a difference in gestational age (median 29.1 weeks,
interquartile range [IQR] 27.4–33.9 versus 22.3 weeks, IQR
Table 2. Neurodevelopmental outcomes, respiratory outcomes and long‐term healthy survival of children participating in follow‐up
Complete case analysis (N = 56)
Assessed for neurodevelopment and health outcomes Amnioinfusion (n = 10) No intervention (n = 4) RR (95% CI)
No neurodevelopmental delaya 8/28 2/28 4.00 (0.93–17.19)
Percentage of all assessed surviving infantsb 80% 50%
Percentage of all included participantsc 28.6% 7.1%
Percentage of all participants with known outcomed 28.6% 8%
Bayley/WPSSI mild delay (−1SD) 8 (28.6%) 2 (7.1%) 4.00 (0.93–17.19)
Bayley/WPSSI severe delay (−2SD) 0 (0%) 0 (0%) —
No respiratory problemse 6/28 3/28 2.00 (0.55–7.22)
Percentage of all assessed surviving infantsb 60% 75%
Percentage of all included participantsc 21.4% 10.7%
Percentage of all participants with known outcomed 21.4% 12%
Respiratory symptoms disturbing daily activitiesf 1 (3.6%) 0 (0%) —
Anti‐asthmatic medicationg 2 (7.1%) 1 (3.6%) 2.00 (0.19–20.82)
Visits to a paediatric pulmonologisth 1 (3.6%) 1 (3.6%) 1.00 (0.7–15.21)
Composite healthy survivori 5/28 2/28 2.50 (0.53–11.83)
Percentage of all assessed surviving infantsb 50% 50%
Percentage of all included participantsc 17.9% 7.1%
Percentage of all participants with known outcomed 17.9% 8%
Data presented as n (%).
a
Neurodevelopmental delay defined as: scores for a mild neurodevelopmental delay with a cut off of −1 SD in any of the 2 indexes of the Bayley‐
III‐NL or in any of the 3 scales of the WPPSI‐III‐NL.
b
Percentage of all infants that were assessed for follow‐up, n = 10 in the amnioinfusion group, n = 4 in the no intervention group.
c
Percentage of all included participants, n = 28 in the amnioinfusion group, n = 28 in the no intervention group.
d
Percentage of participants with a known outcome, n = 28 in the amnioinfusion group, n = 25 in the no intervention group (three infants lost to
follow‐up).
e
Respiratory problems defined as: at least once a week respiratory symptoms interfering with daily activities (i.e. not able to attend school or not
able to play) in the past four weeks, or visits to a paediatric pulmonologist from birth until current age, or use of anti‐asthmatic medication for
respiratory symptoms at least ≥1 time/week.
f
Respiratory symptoms interfering with daily activities (i.e. not able to attend school or not able to play) at least once a week over the past four
weeks.
g
Use of anti‐asthmatic medication at least ≥1 time/week from birth until current age.
h
Visits to a pulmonologist from birth until current age.
i
Healthy survivor defined as: no neurodevelopmental delay or no respiratory problems.
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20.4–24.4, difference in medians 7.7 weeks; 95% CI 5.7–9.9),
latency period from PPROM to delivery (11 weeks, IQR 8.2–
15.2 versus 3.3 weeks, IQR 1.9–5.6, difference in medians
7.4 weeks; 95% CI 5.4–10.1), and single deepest pocket mea-
sured at randomisation: 14.0 mm (7.3–16.5) versus 6.0 mm
(0–12.0), difference in medians 6.0 mm; 95% CI 2.0–11.0)
(Table S10). Mild neurodevelopmental delay was observed in
4/14 children (29%), abnormal sensory processing in 3/14
children (21%), and abnormal behaviour in two children
(14.3%). Five of 14 children (36%) reported respiratory prob-
lems. The composite outcome ‘healthy long‐term survival’
occurred in 7/14 children (50%).
Discussion
Main findings
In women suffering from second‐trimester PROM and oligo-
hydramnios, 30% of children survived until childhood. Sur-
vival with normal development and without respiratory
problems was comparable between children born to mothers
treated with amnioinfusion and mothers managed with no
intervention. Thus, in this small sample, amnioinfusion does
not significantly improve long‐term developmental or respi-
ratory childhood outcomes. These results do not suggest
changing standard care after second‐trimester PROM in
Figure 2. Neurodevelopmental outcomes of children participating in follow up, when analysing data irrespectively of trial assignment.
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clinical practice; however, a larger sample size is warranted
(>56 subjects, >17 survivors) to draw definitive conclusions.
Strengths and limitations
Our study has several strengths. We have provided an
extensive assessment of long‐term outcomes after second‐
trimester PROM and amnioinfusion or no intervention,
and investigated a child’s neurodevelopment, behaviour,
sensory processing, respiratory problems, and health out-
comes in detail using validated instruments and parental
questionnaires. The Bayley‐III‐NL and WPPSI‐III‐NL were
used, both of which are standardised, well‐validated devel-
opmental tests that are highly recommended to evaluate
neurodevelopment in young childhood.11,12 Data were col-
lected by trained healthcare professionals blinded for study
group and in a standardised care setting.
Our study also has limitations. The absolute number of
participating children in this follow‐up study was low due
to high perinatal mortality rates, even though the follow‐up
rate was above the recommended follow‐up thresholds of
60–80%.22 Therefore, results should be interpreted cau-
tiously. Three children lost to follow up were all assigned
to the no intervention group and had PPROM at a lower
gestational age compared with the group of children
assessed for developmental outcomes. As we were unsure
whether these children are growing up without health
problems, we performed a sensitivity analysis, analysing all
children lost to follow up as either having normal outcome
or neurodevelopmental delay. Also, multiple imputations
were used to analyse all children, even though unavoidably,
the results of multiple imputation techniques in small sam-
ple clinical trials will still be complicated by the problem of
attrition.23
It is known that parental socio‐economic disadvantage,
independent of pregnancy and delivery complications, is
associated with abnormal child neurodevelopment.24,25
Adjusting for this confounder was not possible due to the
small sample size.26 Additionally, as socio‐economic status
was not assessed for all women in the original PPROMEXIL‐
III trial, but only in the follow‐up study, it could not be used
as a predictor for imputation for missing values.
This follow‐up study included enough subjects to detect
a difference of −2 SD in neurodevelopmental test scores
with a power of 80% and a two‐sided α of 0.05. However,
no −2 SD differences in test scores were seen in our study.
To detect a difference of 15 points in neurodevelopmental
tests (−1 SD), a larger number of subjects would have been
needed (i.e. 17 children per group) to give adequate power.
One of the mayor limitations concerning all follow‐up
studies of RCTs investigating perinatal interventions is that
the power of a follow‐up study is determined by the sample
and perinatal mortality of the original RCT. Even though a
sample size calculation is often performed in follow‐up
studies, a sample large enough to detect statistical signifi-
cance is regularly not reached. Additionally, when investi-
gating a rare complication in pregnancy, such as second‐
trimester PPROM with an incidence of 0.4–07.%, large
study samples might be hard to obtain unless collaborating
internationally and intercontinentally.
Furthermore, both RCTs (PPROMEXIL‐III and AMI-
PROM) based their power analysis upon the mortality rates
of observational studies.27,28 However, when calculating a
sample size using perinatal mortality rates of these two
RCTs combined in a traditional meta‐analysis, we would
need a sample of 1352 women per group to detect a
decrease of 5% (71–66%), with an alpha of 0.05 and a
power of 80%.9 Thus, both RCTs were underpowered, and
consequently their follow‐up studies as well; larger future
RCTs are therefore needed.
Interpretations
In the AMIPROM study,22 the only other RCT investigat-
ing the efficacy of amnioinfusion for second‐trimester
PROM, long‐term survival without respiratory or neurode-
velopmental disabilities occurred in 4/28 (14.3%) in the
amnioinfusion and 0/28 in the control group (RR 9.0; 95%
CI 0.51–159.70)29 compared with 5/28 (17.9%) and 2/28
(7.1%) (RR 2.50; 95% CI 0.53–11.83) in this study. For
neurodevelopmental outcome, Roberts et al. assessed eight
children in the amnioinfusion group of which five had sev-
ere or mild delay compared with four of the five assessed
children in the expectant management. In our study, we
found two children in both treatment groups with neu-
rodevelopmental delay. Of note, Roberts et al. show a sig-
nificant delay (−2 SD) in three surviving infants, whereas
in our follow‐up study no severe delay was reported. The
overall chance of survival without neurodevelopmental dis-
ability was 4/56 (7.1%) in the AMIPROM trial and 10/56
(17.9%) in our follow‐up study.
When assessing our study population, irrespectively of
trial assignment, 71% of the children survived without
neurodevelopmental delay and 50% had a ‘normal child
outcome’, and were classified as healthy long‐term sur-
vivors. Few other studies have investigated long‐term out-
comes of children born after second‐trimester PROM.30–32
Comparable to our study, all these studies suggest some
neuromotor abnormalities. A retrospective cohort study
published in 2007 reviewed obstetric and neonatal records
for 87 pregnancies with PPROM between 14 and
24 weeks.31 They demonstrated a normal neurological and
developmental outcome at 2 years of age in half of all (6/
12) surviving infants. A comparable cohort study by Rib
et al., published in 1993, showed that 72% of surviving
infants after PPROM <26 weeks would survive without
developmental delay as assessed at 2 years of age.32 Finally,
a small study investigating pregnancies with second‐
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trimester (spontaneous and iatrogenic) PPROM between
14 and 24 weeks’ gestation showed that 71% of infants
survived without neurological and developmental sequelae
at age 4.30
Conclusion
The findings of this follow‐up study suggest that survival
without neurodevelopmental delay or respiratory problems
does not differ between management with amnioinfusion
versus no intervention in the assessed sample of this fol-
low‐up study. The power of our study was insufficient to
identify the ‘true’ potentially beneficial effect of amnioinfu-
sion. Our findings do not suggest a change in management
of second‐trimester PROM and oligohydramnios. Assess-
ment of all survivors in this follow‐up study suggests no
severe or mild delay at school age in 71% of surviving chil-
dren and could be helpful in counselling parents regarding
long‐term developmental sequelae after second‐trimester
PROM and oligohydramnios.
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the Supporting Information section at the end of the
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Figure S1. CONSORT flow diagram.
Figure S2. Forest plot for the risk of the outcome:
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have been randomised prenatally to amnioinfusion or no
intervention.
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Total surviving children n = 17.
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and mean scores) for 14 survivors who have been ran-
domised prenatally to amnioinfusion or no intervention.
Table S4. Pregnancy characteristics and neonatal out-
come in children with a mild neurodevelopmental delay (–
1 SD).
Table S5. Missing subscales Wechsler Preschool and Pri-
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(WPPSI‐III‐NL).
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mester PROM according to treatment assignment.
Table S7. Sensitivity analysis: best case scenario (i.e. all
children lost to follow up are healthy) and worst case sce-
nario (i.e. all children lost to follow up are unhealthy).
Table S8. Behaviour and sensory processing (abnormal
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prenatally to amnioinfusion or no intervention.
Table S9. Health outcomes for 14 survivors who have
been randomised prenatally to amnioinfusion or no inter-
vention.
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